Recent Updates
Recently added Catalysts
CBLL Positive Sentiment Score: 75/100

Ceribell to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Tuesday, December 30, 2025 2 min read
Key Takeaway: Ceribell, Inc. (Nasdaq: CBLL) will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, led by CEO Jane Chao, Ph.D. The presentation will highlight the company's focus on improving diagnosis and management for patients with serious neurological conditions. The Ceribell System, a point-of-care EEG platform, has received FDA clearance and is designed for use in intensive care units and emergency rooms. The conference will feature a live and archived webcast accessible on the Ceribell website.

Market Sentiment Analysis

POSITIVE FACTORS

  • Ceribell will be showcasing its innovations at a high-profile conference.
  • The Ceribell System is FDA-cleared, indicating regulatory approval.
  • The company's technology focuses on unmet needs in acute care settings.

Full Press Release Details

SUNNYVALE, Calif., Dec. 30, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation will take place on Monday, January 12, 2026, at 9:00 am Pacific Standard Time / 12:00 pm Eastern Standard Time.
Event: 44th Annual J.P. Morgan Healthcare Conference
Date: Monday, January 12, 2026
Time: 9:00 am PST / 12:00 pm EST
A live and archived webcast of the presentation will be available in the "Investor Relations" section of the Ceribell website at https://investors.ceribell.com/.
About CeriBell, Inc.
Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA-cleared for use in detecting seizure and delirium in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit www.ceribell.com or follow the company on LinkedIn.
Brian Johnston or Laine Morgan
Investors@ceribell.com

Frequently Asked Questions

When is Ceribell's presentation at the J.P. Morgan Conference?

Ceribell's presentation is on January 12, 2026, at 9:00 am PST.

What is the focus of CeriBell, Inc.?

CeriBell, Inc. focuses on improving diagnosis and management of serious neurological conditions.

What is the Ceribell System designed for?

The Ceribell System is designed for rapid diagnosis and monitoring of neurological patients.

Where can I watch Ceribell's conference presentation?

You can watch it on their website under the 'Investor Relations' section.

Is the Ceribell System FDA-cleared?

Yes, the Ceribell System is FDA-cleared for detecting seizures and delirium.

Tags: CBLL Viatris Investor Conferences Healthcare Ceribell J.P. Morgan Conference neurological conditions FDA-cleared electroencephalography
Last updated: Dec 30, 2025